A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4144 in Participants With Established Atherosclerotic Cardiovascular and Chronic Kidney Disease.
Completed · Phase 1 · Has a placebo group
Conditions studied: Chronic Kidney Disease, Atherosclerotic Cardiovascular Disease
In brief
The purpose of this study is to evaluate the safety, tolerability and the pharmacodynamics (PD) of AZD4144 following oral administration in participants with atherosclerotic cardiovascular disease (ASCVD) and chronic kidney disease (CKD).
Key facts
- Study ID
- NCT06675175
- Run by
- AstraZeneca
- People needed
- 29
- Starts
- 2024-12-09
- Expected to finish
- 2025-10-27
- Last updated by the study team
- 2025-11-25
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Research Site — Glendale, California, United States
- Research Site — Daytona Beach, Florida, United States
- Research Site — Jacksonville, Florida, United States
- Research Site — Miami, Florida, United States
- Research Site — Port Orange, Florida, United States
- Research Site — Tampa, Florida, United States
- Research Site — Farmington Hills, Michigan, United States
- Research Site — The Bronx, New York, United States
- Research Site — Sherman, Texas, United States
- Research Site — Pleven, Bulgaria
- Research Site — Sofia, Bulgaria
- Research Site — Gyöngyös, Hungary
- Research Site — Kistarcsa, Hungary
- Research Site — Bucharest, Romania
- Research Site — Cluj-Napoca, Romania
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.